Therapeutic methods of using O-desulfated heparin derivatives

Abstract

Compositions and methods of making selectively O-desulfated heparin compositions, preferably 6-O-desulfated heparin compositions, wherein the methods permit regulating the degree of 6-O-desulfation. The compositions are useful for treating various diseases, including cancer, angiogenesis, shock, ischemia reperfusion injury, inflammation, and cardiovascular diseases including restenosis.

What is claimed is: 
     
       1. A method for inhibiting angiogenesis or treating a disease selected from the group consisting of cancer, ischemia reperfusion injury, inflammation, restenosis, and cardiovascular diseases, in an animal host, comprising administering to said animal host an effective amount of a composition comprising a substantially unfragmented N-sulfated 6-O-desulfated heparin, or an N-sulfated 6-O-desulfated heparin fragment, which heparin or heparin fragment has less than 30% of the anticoagulant activity of unmodified heparin. 
     
     
       2. The method of claim 1 wherein said heparin or heparin fragment is less than approximately 34% 6-O-sulfated and up to about 67% 2-O-sulfated. 
     
     
       3. A method for inhibiting heparanase, comprising contacting said heparanase with an effective amount of a composition comprising a substantially unfragmented N-sulfated 6-O-desulfated heparin or an N-sulfated 6-O-desulfated heparin fragment, which heparin or heparin fragment has less than 30% of the anticoagulant activity of unmodified heparin. 
     
     
       4. The method of claim 3 wherein said heparin or heparin fragment is less than approximately 34% 6-O-sulfated and up to about 67% 2-O-sulfated. 
     
     
       5. A method for inhibiting angiogenesis in an animal suffering from unwanted angiogenesis, comprising administering to said animal an effective amount of a composition comprising a substantially unfragmented N-sulfated 6-O-desulfated heparin or an N-sulfated 6-O-desulfated heparin fragment which heparin or heparin fragment has less than 30% of the anticoagulant activity of unmodified heparin. 
     
     
       6. The method of claim 5 wherein said heparin or heparin fragments are less than approximately 34% 6-O-sulfated and up to about 67% 2-O-sulfated. 
     
     
       7. The method of claim 2 wherein said heparin or heparin fragment is less than 34% 6-O-sulfated and up to 67% 2-O-sulfated. 
     
     
       8. The method of claim 7 wherein said heparin or heparin fragment is 12-26% 6-O-sulfated and 28-50% 2-O-sulfated. 
     
     
       9. The method of claim 7 wherein said heparin or heparin fragment is less than 13% 6-O-sulfated and 14-18% 2-O-sulfated. 
     
     
       10. The method of claim 4 wherein said heparin or heparin fragment is less than 34% 6-O-sulfated and up to 67% 2-O-sulfated. 
     
     
       11. The method of claim 10 wherein said heparin or heparin fragment is 12-26% 6-O-sulfated and 28-50% 2-O-sulfated. 
     
     
       12. The method of claim 10 wherein said heparin or heparin fragment is less than 13% 6-O-sulfated and 14-18% 2-O-sulfated. 
     
     
       13. The method of claim 6 wherein said heparin or heparin fragment is less than 34% 6-O-sulfated and up to 67% 2-O-sulfated. 
     
     
       14. The method of claim 13 wherein said heparin or heparin fragment is 12-26% 6-O-sulfated and 28-50% 2-O-sulfated. 
     
     
       15. The method of claim 13 wherein said heparin or heparin fragment is less than 13% 6-O-sulfated and 14-18% 2-O-sulfated. 
     
     
       16. The method of claim 7 wherein said composition is administered orally, subcutaneously, or intravenously.